Navigation Links
New Form of Painkiller May Fight Colon Cancer
Date:4/21/2010

Lab tests suggest that variation of naproxen might nip cancer in the bud, expert says,,

WEDNESDAY, April 21 (HealthDay News) -- Adding to previous research suggesting that painkillers can reduce the risk for colon cancer, researchers report that an investigational form of the drug naproxen blocks a molecular process that leads to the disease.

Commonly known by such brand names as Aleve, Anaprox and Naprosyn, the standard form of naproxen is a generic pain medication.

Though the drug has been tested only in the laboratory, not on people, "it appears that the investigational form of naproxen we studied may be more effective than standard naproxen in inhibiting colorectal tumor development," Margie Clapper, co-leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center, said in a news release from the center. "An added benefit would be the reduced gastrointestinal toxicity of this novel type of naproxen."

Researchers found that the new type of naproxen, known as NO-naproxen, appeared to block a signaling pathway that plays a role in the formation of colorectal cancer.

Based on laboratory data, "we think that NO-naproxen is much better than naproxen in nipping this whole process in the bud," Clapper said.

The scientists are testing their finding in mice but do not yet have the results.

The study findings were scheduled to be released at the annual meeting of the American Association for Cancer Research, April 17 to 21 in Washington D.C.

More information

The American Cancer Society has more about colon cancer.



-- Randy Dotinga



SOURCE: Fox Chase Cancer Center, news release, April 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Another perk of painkillers? Decreased hormone levels may reduce cancer risk
2. Painkillers Lower Estrogen Levels, May Explain Cancer Reduction Risk
3. Overdoses From Prescription Painkillers on the Rise
4. Makers of Powerful Painkillers Present Safety Plans
5. San Francisco Firefighters: Increased Risk for Bladder Cancer – Testing Underway
6. Firefighters Walk Over 60,000 Miles in Blue Cross Blue Shield of Massachusetts' Fitness Challenge
7. Hormone Therapy May Fight Resistant Prostate Cancer
8. Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010
9. Author Erin Morrow Still Releases "Fighting MS: Strength in Numbers"
10. Scientists Find Clues to How the Body Fights Off HIV
11. Sokolove Law Helps Thousands of Consumers Fight Unfair Disability Insurance Denial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: